Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma
J Neurosurg
.
2018 Oct;129(4):1104-1105.
doi: 10.3171/2018.6.JNS181418.
Epub 2018 Aug 17.
Authors
Michael D Jenkinson
1
2
,
Damien C Weber
3
,
Brian J Haylock
4
,
Frances C Sherratt
5
,
Bridget Young
5
,
Michael Weller
6
,
Helen Bulbeck
7
,
Giovanna Culeddu
8
,
Dyfrig A Hughes
8
,
Alice Brain
4
,
Kumar Das
1
,
Matthias Preusser
9
,
Priya Francis
2
,
Carrol Gamble
2
Affiliations
1
1The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom.
2
2Institute of Translational Medicine, University of Liverpool, United Kingdom.
3
3Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
4
4Clatterbridge Cancer Centre, Wirral, United Kingdom.
5
5Institute of Psychology, Health and Society, University of Liverpool, United Kingdom.
6
6University Hospital Zurich, Switzerland.
7
7brainstrust charity, Cowes, Isle of Wight, United Kingdom.
8
8Centre for Health Economics and Medicines Evaluation, University of Bangor, United Kingdom; and.
9
9Comprehensive Cancer Centre Vienna, Medical University of Vienna, Austria.
PMID:
30117772
DOI:
10.3171/2018.6.JNS181418
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Meningeal Neoplasms*
Meningioma*
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic